Dulanermin, a soluble, recombinant human TRAIL (rhTRAIL) formulation comprising of the extracellular portion of TRAIL (amino acids 114–281) was the first TRAIL variant tested for the treatment of cancer [21,22]. This evidence concerns the gene TNFSF10 and cancer.